Journal article
Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial
Abstract
BACKGROUND: Direct oral anticoagulants are administered in fixed doses irrespective of body weight, but guidelines recommend against their use in patients with extremes of body weight.
OBJECTIVES: This study determined the effects of dual-pathway inhibition antithrombotic regimen (rivaroxaban 2.5 mg twice daily plus aspirin 100 mg/day) compared with aspirin Halone across a range of patient body mass indexes (BMIs) and body weights.
Authors
Guzik TJ; Ramasundarahettige C; Pogosova N; Lopez-Jaramillo P; Dyal L; Berkowitz SD; Muehlhofer E; Bhatt DL; Fox KAA; Yusuf S
Journal
Journal of the American College of Cardiology, Vol. 77, No. 5, pp. 511–525
Publisher
Elsevier
Publication Date
February 2021
DOI
10.1016/j.jacc.2020.11.061
ISSN
0735-1097